ID
25466
Description
Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease
Keywords
Versions (4)
- 8/17/17 8/17/17 -
- 8/23/17 8/23/17 -
- 9/4/17 9/4/17 -
- 9/4/17 9/4/17 -
Uploaded on
September 4, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
visit 1 & 4 laboratory evaluation urinalysis starting dose of ropinirole Parkinson's Disease 101468/166
visit 1 & 4 laboratory evaluation urinalysis starting dose of ropinirole Parkinson's Disease 101468/166
Description
Number of Visit
Alias
- UMLS CUI-1
- C1549755
Description
URINALYSIS
Alias
- UMLS CUI-1
- C0042014
Description
pH
Alias
- UMLS CUI-1
- C0042044
Description
Protein
Alias
- UMLS CUI-1
- C0262923
Description
Glucose
Alias
- UMLS CUI-1
- C0004076
Description
Blood
Alias
- UMLS CUI-1
- C0018965
Description
Bilirubin
Alias
- UMLS CUI-1
- C0042040
Similar models
visit 1 & 4 laboratory evaluation urinalysis starting dose of ropinirole Parkinson's Disease 101468/166
C0011008 (UMLS CUI [1,2])